Skip to contentG
GeneDx Holdings Corp.
G
WGSGeneDx Holdings Corp. Q3 2025 · 10-Q
Revenue$116.74M$116.74M+51.9% vs Q3 2024 Net Income-$7.64M-$7.64MN/M vs Q3 2024 EPS Diluted-$0.27-$0.27N/M vs Q3 2024 Gross Profit$84,527,000+76.7% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
GeneDx Holdings Corp. · CIK 1818331 · Engraved from SEC EDGAR
Operating Cash Flowderived$15,767,000N/M Free Cash Flowderived$9,595,000N/M Margins · derivedGross margin72.4%+10.2 pt vs Q3 2024
Operating margin-2.8%+7.3 pt vs Q3 2024
Net margin-6.5%+4.3 pt vs Q3 2024
ended Sep 30, 2025 · filed Oct 28, 2025 · 28 d after period end